These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 2427300)

  • 21. Possible nonspecific associations between malaria and HTLV-III/LAV.
    Biggar RJ
    N Engl J Med; 1986 Aug; 315(7):457-8. PubMed ID: 3016540
    [No Abstract]   [Full Text] [Related]  

  • 22. [High prevalence of anti-LAV/HTLV-III antibodies in a population of heroin addicts from the Nice area].
    Reynes J; Quaranta JF; Pesce A; Bernard E; Fuzibet JG; Maiolini R; Cassuto JP; Dellamonica P
    Presse Med; 1985 Dec; 14(46):2348-9. PubMed ID: 3003734
    [No Abstract]   [Full Text] [Related]  

  • 23. [Evaluation of 3 immuno-enzyme kits for the detection of anti-LAV antibodies. Comparison with confirmation tests. Study Subgroup of the National Blood Transfusion Society].
    Rev Fr Transfus Immunohematol; 1985 Sep; 28(4):325-44. PubMed ID: 3001897
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Human retroviral env and gag polypeptides: serologic assays to measure infection.
    Kanner SB; Cheng-Mayer C; Geffin RB; Parks WP; Beltz GA; Arthur LO; Samuel KP; Papas TS
    J Immunol; 1986 Jul; 137(2):674-8. PubMed ID: 3014000
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Preventive measures against HTLV-III/LAV infections among hemophiliacs and their relatives].
    Evensen SA; Frøland SS; Glomstein A
    Tidsskr Nor Laegeforen; 1986 Jan; 106(1):19-21. PubMed ID: 3006278
    [No Abstract]   [Full Text] [Related]  

  • 26. HTLV-III antibody in intravenous drug abusers of metropolitan Barcelona, Spain.
    Tor J; Muga R; Argelagues E; Rey-Joly C; Foz M; Ribas-Mundó M
    Arch Intern Med; 1986 Apr; 146(4):805. PubMed ID: 3008680
    [No Abstract]   [Full Text] [Related]  

  • 27. Disinfection and inactivation of HTLV-III/LAV.
    Ronalds CJ; Grint PC; Kangro HD
    J Infect Dis; 1986 May; 153(5):996-7. PubMed ID: 3009641
    [No Abstract]   [Full Text] [Related]  

  • 28. The prevalence of HTLV-III/LAV antibodies in heterosexuals.
    Whittington WL; Kraus SJ; Lee F; Nahmias AJ
    JAMA; 1986 Apr; 255(13):1702-3. PubMed ID: 3005674
    [No Abstract]   [Full Text] [Related]  

  • 29. [AIDS and the current significance of serological studies for the presence of antibodies against LAV/HTLV III].
    van Gestel WJ
    Ned Tijdschr Geneeskd; 1985 Feb; 129(5):233-4. PubMed ID: 2983238
    [No Abstract]   [Full Text] [Related]  

  • 30. [Prevalence of antibodies against the lymphadenopathy-associated virus/human T-cell lymphotropic virus type III (LAV/HTLV) in a population of homosexuals in Mexico].
    Sierra Madero JG; Ponce de León S; Ruiz Palacios G; Tinoco JC; Calva JJ; Zamora EE
    Salud Publica Mex; 1986; 28(2):180-5. PubMed ID: 3014666
    [No Abstract]   [Full Text] [Related]  

  • 31. [Sero-epidemiology of HTLV-III/LAV antibodies in French-speaking Switzerland].
    Stroun J
    Rev Med Suisse Romande; 1985 Nov; 105(11):1055-7. PubMed ID: 3003866
    [No Abstract]   [Full Text] [Related]  

  • 32. HTLV-III antibody in Swiss and English intravenous drug abusers.
    Mortimer PP; Vandervelde EM; Jesson WJ; Pereira MS; Burkhardt F
    Lancet; 1985 Aug; 2(8452):449-50. PubMed ID: 2863476
    [No Abstract]   [Full Text] [Related]  

  • 33. [Methods for laboratory studies of LAV/HTLV III infection and reliability of the results].
    van den Akker R
    Ned Tijdschr Geneeskd; 1986 Jul; 130(28):1269-72. PubMed ID: 3018597
    [No Abstract]   [Full Text] [Related]  

  • 34. [Research on anti-HTLV-III antibodies: validity of methods].
    Achilli G; Cattaneo E
    Riv Emoter Immunoematol; 1985; 32(2):190-4. PubMed ID: 3003877
    [No Abstract]   [Full Text] [Related]  

  • 35. Elimination of human immunodeficiency virus from immunoglobulin preparations.
    Lancet; 1986 May; 1(8491):1217-8. PubMed ID: 2422515
    [No Abstract]   [Full Text] [Related]  

  • 36. Heat inactivation of serum may interfere with HTLV-III/LAV serology.
    van den Akker R; Hekker AC; Osterhaus AD
    Lancet; 1985 Sep; 2(8456):672. PubMed ID: 2863663
    [No Abstract]   [Full Text] [Related]  

  • 37. [Immunologic properties, aggregate content and half-life of various human i.v. gamma globulin preparations].
    Ring J; Duswald KH; Seifert J; Brendel W
    Langenbecks Arch Chir; 1976; Suppl():63-7. PubMed ID: 73997
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Anti-HIV antibodies in patients treated with intravenous gammaglobulins].
    Ohno T; Kanoh T; Fujii H; Okada T; Funakoshi N; Uchino H
    Nihon Ketsueki Gakkai Zasshi; 1987 May; 50(3):649-53. PubMed ID: 2447736
    [No Abstract]   [Full Text] [Related]  

  • 39. Virus related to but not identical with LAV/HTLV-III in Cameroon.
    Fleury HJ; Babin M; Bonnici JF; Bailly C; Chancerel B; Le Bras M
    Lancet; 1986 Apr; 1(8485):854. PubMed ID: 2870334
    [No Abstract]   [Full Text] [Related]  

  • 40. Safety of therapeutic immune globulin preparations with respect to transmission of human T-lymphotropic virus type III/lymphadenopathy-associated virus infection.
    Centers for Disease Control (CDC)
    MMWR Morb Mortal Wkly Rep; 1986 Apr; 35(14):231-3. PubMed ID: 3007971
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.